| Sign In to gain access to subscriptions and/or personal tools. |
Vascular and connective tissue diseases in the paediatric worldDepartment of Paediatrics, Rheumatology Unit, University of Florence, Firenze, Italy, falcini{at}unifi.it Despite the fact that in recent decades many advances have been made in classification, outcomes measurements and therapeutic regimens, connective tissue diseases remain a challenge for paediatric rheumatologists. Corticosteroids are still the first choice therapy in juvenile systemic lupus erythematosus (SLE); however, it is time for a new therapeutic approach with immunosuppressant drugs in order to obtain a more prolonged survivaland reduced organ system damage. A preventionof relapse of thromboembolic phenomena using low-dose aspirin is strongly suggested in children with anticardiolipin antibodies, particularly in those with SLE. The long-term prognosis in juvenile dermatomyositisis significantly improved due to a more aggressivetreatment with corticosteroidsand methotrexate. The treatment of Henoch-Schöenlein purpura is still under debate, and no agreement has been reached regarding the role of corticosteroids in the prevention of renal involvement. The management of the acute phase of Kawasaki disease is now well established, although there is controversy regarding the role of corticosteroids. It is still under debate how and whether to treat patients who do not fulfil the diagnostic criteria. Polyarteritis nodosa is a disease at risk of death and requires an aggressive approach with corticosteroids and immunosuppressants, while cutaneous polyarteritis needs a close control of an underlying streptococcus infection and prophylaxis with benzatin-penicillin to prevent relapses.
Key Words: connective tissue diseases in childhood • cutaneous panarterytis • Henoch-Schöenlein purpura • juvenile dermatomyositis • juvenile SLE • Kawasaki disease • PAN
Lupus, Vol. 13, No. 2,
77-84 (2004) |
|||
 |
|
|
 |
Sign In to gain access to subscriptions and/or personal tools.
